Company Description
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders.
It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex.
Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jul 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 166 |
| CEO | Dr. Scott N. Braunstein M.D. |
Contact Details
Address: 5 Radnor Corporate Center Suite 500, 100 Matsonford Rd Radnor, Pennsylvania 19087 United States | |
| Phone | 484-801-4670 |
| Website | marinuspharma.com |
Stock Details
| Ticker Symbol | MRNS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001267813 |
| CUSIP Number | 56854Q200 |
| ISIN Number | US56854Q2003 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Scott N. Braunstein M.D. | Chief Executive Officer, President and Chairman |
| Steven E. Pfanstiel C.M.A., M.B.A. | Chief Operating Officer, Chief Financial Officer and Treasurer |
| Dr. Joseph Hulihan M.D. | Chief Medical Officer |
| Dr. Alex Aimetti Ph.D. | Chief Scientific Officer |
| Sonya Weigle | Senior Vice President of Investor Relations, Human Resources and Corporate Affairs |
| Martha E. Manning Esq., J. D. | Senior Vice President, General Counsel and Secretary |
| Molly Cameron | Director of Corporate Communications and Investor Relations |
| Dr. Kimberly A. McCormick Pharm.D. | Chief Regulatory and Quality Assurance Officer |
| Thomas J. Lyons | Chief Business Officer |
| Christina Shafer | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 17, 2024 | 8-K | Current Report |
| Jun 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 6, 2024 | 8-K | Current Report |
| May 24, 2024 | 8-K | Current Report |
| May 17, 2024 | 8-K | Current Report |
| May 8, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| Apr 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 19, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |